TBC1D2-IN-1
TBC1D2-IN-1 is a potent orally active and selective TBC1D2 inhibitor with a Kd of 1.1 μM. TBC1D2-IN-1 selectively inhibits TBC1D2-mediated GTP hydrolysis on RAB7A-GTP, promotes RAB7A accumulation on lysosomal membranes, and induces apoptosis and autophagy. TBC1D2-IN-1 exerts selective antiproliferative activity cancer cells. TBC1D2-IN-1 can be used for the research of cervical carcinoma.
For research use only. We do not sell to patients.
- Formula: C34H35F3N2O3
- Molecular Weight:576.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Caspase-3 |
Bax |
Bcl-2 |
In Vitro
TBC1D2-IN-1 (compound A1) (0.1-20 μM) binds selectively to the PH domain of TBC1D2, showing weaker binding to Top 1 and no binding to Hsp90[1].
TBC1D2-IN-1 (2 days) potently and selectively inhibits proliferation of HeLa cells with an IC50 of 0.43 μM and inhibits proliferation of A549, HepG2, and BEAS-2B cells with IC50 values of 0.56, 0.79, and 1.5 μM, respectively[1].
TBC1D2-IN-1 (0.5-1.5 μM; 24 h) induces dose-dependent accumulation of RAB7A on the lysosomal membrane of HeLa cells[1].
TBC1D2-IN-1 (0.5-2 μM; 48 h) induces concentration-dependent upregulation of RAB7A protein levels in HeLa cells[1].
TBC1D2-IN-1 (0.5-2 μM; 48 h) induces concentration-dependent decreases in TBC1D2 and VEGFR2 protein levels in HeLa cells after 48 h of treatment, with no significant effects on Top 1 or Hsp90 levels[1].
TBC1D2-IN-1 (0.5-2.5 μM; 24 h) induces potent autophagy in HeLa cells[1].
TBC1D2-IN-1 (0.1-10 μM; 1 h) induces a biphasic change in TBC1D2 protein levels in HeLa cells[1].
TBC1D2-IN-1 (0.5-2.5 μM; 24 h) induces a triphasic apoptotic response in HeLa cells[1].
TBC1D2-IN-1 (0.5-2.5 μM; 24 h) induces a non-monotonic change in the G2/M phase fraction of HeLa cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HeLa cells
-
Concentration:0.5; 1.5 μM
-
Incubation Time:24 h
-
Result:Induced dose-dependent accumulation of RAB7A on the lysosomal membrane, visible as distinct punctate staining in treated cells compared to the diffuse cytoplasmic staining in control cells.
-
Cell Line:HeLa cells
-
Concentration:0.5; 1; 1.5; 2 μM
-
Incubation Time:48 h
-
Result:Induced a concentration-dependent increase in RAB7A protein levels.
Caused a statistically significant 2.2-fold increase in RAB7A protein levels at 2 μM compared to control.\n
Induced a concentration-dependent decrease in TBC1D2 and VEGFR2 protein levels.
Caused no significant changes in Top 1 or Hsp90 protein levels.\n
Induced dynamic changes in apoptotic regulators: p53 levels showed a modest initial increase followed by a decrease, caspase-3 and Bcl-2 levels progressively declined, and Bax levels initially decreased then markedly increased at 2 μM.
-
Cell Line:HeLa cells
-
Concentration:0.5; 1; 1.5; 2; 2.5 μM
-
Incubation Time:24 h
-
Result:Induced a biphasic response in lysosomal fluorescence intensity: fluorescence increased in a concentration-dependent manner up to 1.5 μM, with a 40-fold increase relative to control, then decreased at 2.5 μM due to lysosomal impairment from apoptosis.
-
Cell Line:HeLa cells
-
Concentration:0.1; 0.5; 1; 3; 10 μM
-
Incubation Time:1 h
-
Result:Induced a biphasic change in TBC1D2 fluorescence intensity within 1 h: levels decreased at 0.1 μM, rebounded to a 1.6-fold increase at 1 μM, then decreased again at 10 μM compared to control.
-
Cell Line:HeLa cells
-
Concentration:0.5; 1; 1.5; 2; 2.5 μM
-
Incubation Time:24 h
-
Result:Induced a triphasic apoptotic response: the percentage of apoptotic cells increased from 4% (control) to 26% at 1.5 μM, decreased to 16% at 2 μM, then sharply rose to 94% at 2.5 μM.
-
Cell Line:HeLa cells
-
Concentration:0.5; 1; 1.5; 2; 2.5 μM
-
Incubation Time:24 h
-
Result:Induced a non-monotonic change in the G2/M phase fraction: the proportion increased from 11% (control) to 34% at 0.5 μM, decreased to 4% at 1 μM, then gradually rose to 54% at 2.5 μM.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude subcutaneously injected with HeLa cells[1]
-
Dosage:40 mg/kg
-
Administration:p.o.; every other day; 28 days
-
Result:Achieved a 49% tumor growth inhibition rate.
Induced extensive areas of tumor necrosis via H&E staining.
Exhibited no significant body weight loss relative to controls.
Caused only mild, gefitinib-comparable histopathological alterations in major organs, including mild capillary wall thickening in lungs and occasional tubular swelling and edema in kidneys.
Chemical Information
-
Molecular Weight 576.65
-
Formula C34H35F3N2O3
-
SMILES
O=C1N(C[C@@]2([H])[C@@]3([H])[C@]4([H])CCCN3CCC2)[C@]4([H])CC/C1=C\C5=CC(C=CC(OCC6=CC=C(OC(F)(F)F)C=C6)=C7)=C7C=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)